XOSPATA
40mgXOSPATA40mg
XOSPATA (Gilteritinib) 40mg is a potent FLT3 inhibitor for relapsed/refractory FLT3-mutated acute myeloid leukemia (AML) by Astellas Pharma.
Key Benefits
- Significantly improved overall survival vs chemotherapy (9.3 vs 5.6 months)
- Targets both FLT3-ITD and FLT3-TKD mutations
- Also inhibits AXL kinase to overcome resistance
- Convenient once-daily oral dosing
- FDA breakthrough therapy designation
- Higher complete remission rate (34% vs 15.3%)
Contact Us for Pricing
Get competitive wholesale pricing for XOSPATA 40mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How XOSPATA Works
Gilteritinib works by selectively inhibiting the FLT3 receptor tyrosine kinase, a key driver of leukemic cell proliferation in FLT3-mutated AML. FLT3-ITD mutations cause constitutive activation of the FLT3 receptor, leading to uncontrolled cell growth and survival.
By binding to and inhibiting the FLT3 receptor, gilteritinib blocks downstream signaling pathways including STAT5, RAS/MAPK, and PI3K/AKT that drive leukemic cell proliferation and survival. Gilteritinib also inhibits AXL kinase, which is implicated in FLT3 inhibitor resistance mechanisms.
This dual FLT3/AXL inhibition provides a more comprehensive blockade compared to first-generation FLT3 inhibitors, potentially overcoming resistance mechanisms and achieving deeper responses in relapsed/refractory AML patients.
About XOSPATA 40mg
XOSPATA (gilteritinib) 40mg film-coated tablets by Astellas Pharma is a breakthrough targeted therapy for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring FLT3 mutations. Approved by the FDA in November 2018, Xospata demonstrated significantly improved overall survival compared to salvage chemotherapy in the pivotal ADMIRAL Phase 3 trial. Gilteritinib is a potent, selective inhibitor of FLT3 receptor tyrosine kinase, targeting both FLT3-ITD (internal tandem duplication) and FLT3-TKD (tyrosine kinase domain) mutations. FLT3 mutations are found in approximately 30% of AML patients and are associated with poor prognosis and high relapse rates. As a licensed pharmaceutical supplier based in Turkey, we provide authentic Astellas XOSPATA with complete documentation, certificate of authenticity, and competitive wholesale pricing for hospitals, hematology clinics, and pharmaceutical distributors worldwide. Contact us via WhatsApp for current availability, bulk pricing, and international shipping options.
Common Uses
- Relapsed or refractory FLT3-mutated acute myeloid leukemia (AML)
- FLT3-ITD positive AML after prior therapy failure
- FLT3-TKD mutated AML in relapsed/refractory setting
Dosage Information
XOSPATA dosing for relapsed/refractory FLT3-mutated AML:
Recommended Dose:
Dose Modifications:
Duration:
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store below 30°C (86°F). No refrigeration required. Store in original packaging to protect from moisture and light. Keep out of reach of children. Shelf life: 36 months.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About XOSPATA
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
